Clinica De Oftalmologia De Cordoba S.L.
- Address
- lock Available on a paid plan
Eye Diseases
The clinic’s research program targets major eye diseases such as neovascular and atrophic macular degeneration, focusing on innovative treatments that aim to preserve or improve vision.
- Evaluation of a Port Delivery System with ranibizumab for long‑term management of wet AMD.
- Assessment of RGX‑314 gene therapy as a novel approach for neovascular disease.
- Combination therapy using OPT‑302 with ranibizumab to enhance efficacy in neovascular AMD.
- Comparison of faricimab versus standard anti‑VEGF agents.
- Investigation of ONL1204 to slow progression of geographic atrophy.
- Study of cenegermin ophthalmic solution for healing persistent corneal epithelial defects.
Clinica De Oftalmologia De Cordoba S.L. provides a dedicated environment for advancing ocular therapeutics.
Immune System Diseases
Research at the site also addresses disorders of the immune system affecting the orbit, particularly Thyroid Eye Disease and related Graves’ ophthalmopathy.
- Safety and efficacy of varying teprotumumab treatment durations in active TED.
- Evaluation of the IV biologic LASN01 for reducing inflammation and proptosis.
- Subcutaneous dosing studies of VRDN‑003 in both active and chronic TED.
- Infusion study of VRDN‑001 assessing long‑term outcomes in chronic disease.
- Phase evaluation of efgartigimod PH20 for immune‑mediated eye involvement.
- Dose‑ranging trial of TOUR006 targeting proptosis reduction.
- Comparison of K1‑70 versus placebo for exophthalmos improvement.
These studies aim to refine immunomodulatory strategies and improve quality of life for patients with orbital autoimmune conditions.
Ocular Physiological Phenomena
The institution explores fundamental ocular processes, employing advanced delivery platforms and monitoring visual function to enhance therapeutic outcomes.
- Long‑term safety monitoring of intravitreal injections and their impact on visual acuity stability.
- Pharmacokinetic profiling of sustained‑release devices for continuous drug exposure.
- Investigation of ocular surface healing dynamics using cenegermin in corneal defects.
- Assessment of physiological responses to combined anti‑VEGF regimens.
By linking physiological insights with clinical testing, the site advances both basic and translational ophthalmology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Viridian Therapeutics Inc.1active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Viridian Therapeutics Inc.4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinica De Oftalmologia De Cordoba S.L.
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Janssen Cilag International | Phase II | Not Recruiting | Aug 2023 | Feb 2026 |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ranibizumab | 5 | Unknown | 2021-09-23 | 2024-06-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.